Accelerated Pharma (Accelerated Pharma) Receivables Turnover : 0.00 (As of Mar. 2017)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Accelerated Pharma's Revenue for the three months ended in Mar. 2017 was $0.00 Mil. Accelerated Pharma's average Accounts Receivable for the three months ended in Mar. 2017 was $0.00 Mil.

Accelerated Pharma Receivables Turnover Historical Data

The historical data trend for Accelerated Pharma's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Receivables Turnover Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Receivables Turnover

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Receivables Turnover	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Accelerated Pharma's Receivables Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerated Pharma's Receivables Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's Receivables Turnover falls into.

Accelerated Pharma Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Accelerated Pharma's Receivables Turnover for the fiscal year that ended in Dec. 2016 is calculated as

	Receivables Turnover (A: Dec. 2016 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2016 )	/ (	(Accounts Receivable (A: Dec. 2015 )	+	Accounts Receivable (A: Dec. 2016 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Accelerated Pharma's Receivables Turnover for the quarter that ended in Mar. 2017 is calculated as

	Receivables Turnover (Q: Mar. 2017 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2017 )	/ (	(Accounts Receivable (Q: Dec. 2016 )	+	Accounts Receivable (Q: Mar. 2017 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Accelerated Pharma (NAS:ACCP) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Accelerated Pharma Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines